Bayer's replacement antibody

Bayer AG's new mAb could treat hemophilia patients who have neutralizing antibodies against coagulation factors, and avoid the frequent IV infusions of factor replacement therapy.

In a departure from Bayer AG's historical focus on treating hemophilia with factor replacement therapy, researchers at the pharma have identified an antibody that could supplant its factor-based therapies in the long term by providing a treatment that avoids problems caused by neutralizing antibodies and is far more convenient for patients. ...